Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial.

ABSTRACT:

Aims

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used in circulatory failure. The main indications are cardiogenic shock, post-cardiotomy cardiac failure, and refractory cardiac arrest. However, VA-ECMO weaning is particularly challenging, and weaning failure is reported to be as high as 50%, with increased related mortality. Levosimendan is a novel long acting effect inodilator used in cardiogenic shock and terminal heart failure decompensation. Levosimendan use in VA-ECMO patients seems to reduce weaning failure regardless of the initial aetiology and to reduce mortality when administrated early after VA-ECMO initiation. However, studies are limited to retrospective analyses and reported case series. The aim of the WEANILEVO trial is to evalua

SUBMITTER: Ellouze O 

PROVIDER: S-EPMC8318420 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature